Aclarion (ACON) Competitors $7.50 -0.18 (-2.34%) Closing price 07/3/2025 03:51 PM EasternExtended Trading$7.50 0.00 (-0.07%) As of 07/3/2025 04:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock ACON vs. ENZ, BRTX, MGRX, SSY, BGLC, VSEE, ATIP, DHAC, OTRK, and NIVFShould you be buying Aclarion stock or one of its competitors? The main competitors of Aclarion include Enzo Biochem (ENZ), Biorestorative Therapies (BRTX), Mangoceuticals (MGRX), SunLink Health Systems (SSY), BioNexus Gene Lab (BGLC), VSee Health (VSEE), ATI Physical Therapy (ATIP), Digital Health Acquisition (DHAC), Ontrak (OTRK), and NewGenIvf Group (NIVF). These companies are all part of the "healthcare" industry. Aclarion vs. Its Competitors Enzo Biochem Biorestorative Therapies Mangoceuticals SunLink Health Systems BioNexus Gene Lab VSee Health ATI Physical Therapy Digital Health Acquisition Ontrak NewGenIvf Group Enzo Biochem (NYSE:ENZ) and Aclarion (NASDAQ:ACON) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, earnings, institutional ownership, dividends, valuation and risk. Do insiders and institutionals have more ownership in ENZ or ACON? 36.9% of Enzo Biochem shares are owned by institutional investors. Comparatively, 7.5% of Aclarion shares are owned by institutional investors. 11.4% of Enzo Biochem shares are owned by company insiders. Comparatively, 0.8% of Aclarion shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has more risk & volatility, ENZ or ACON? Enzo Biochem has a beta of 1.19, suggesting that its share price is 19% more volatile than the S&P 500. Comparatively, Aclarion has a beta of 1.34, suggesting that its share price is 34% more volatile than the S&P 500. Is ENZ or ACON more profitable? Enzo Biochem has a net margin of -75.34% compared to Aclarion's net margin of -12,227.10%. Enzo Biochem's return on equity of -7.96% beat Aclarion's return on equity.Company Net Margins Return on Equity Return on Assets Enzo Biochem-75.34% -7.96% -5.49% Aclarion -12,227.10%-126.89%-106.61% Do analysts recommend ENZ or ACON? Aclarion has a consensus target price of $11,758.50, indicating a potential upside of 156,680.00%. Given Aclarion's stronger consensus rating and higher probable upside, analysts plainly believe Aclarion is more favorable than Enzo Biochem.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Enzo Biochem 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Aclarion 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media favor ENZ or ACON? In the previous week, Enzo Biochem and Enzo Biochem both had 1 articles in the media. Aclarion's average media sentiment score of 0.83 beat Enzo Biochem's score of 0.00 indicating that Aclarion is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enzo Biochem 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aclarion 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher valuation & earnings, ENZ or ACON? Aclarion has lower revenue, but higher earnings than Enzo Biochem. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEnzo Biochem$29.09M0.59-$26.08MN/AN/AAclarion$54.60K79.94-$6.99MN/AN/A SummaryEnzo Biochem and Aclarion tied by winning 6 of the 12 factors compared between the two stocks. Get Aclarion News Delivered to You Automatically Sign up to receive the latest news and ratings for ACON and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ACON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACON vs. The Competition Export to ExcelMetricAclarionMedical Services IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.37M$7.31B$5.50B$9.01BDividend YieldN/A2.77%5.38%4.04%P/E RatioN/A27.9427.6020.30Price / Sales79.9428.19369.09103.84Price / CashN/A22.0836.6357.47Price / Book0.156.698.055.68Net Income-$6.99M$233.06M$3.18B$249.13M7 Day Performance3.16%1.74%2.82%3.30%1 Month Performance12.61%3.97%3.70%5.20%1 Year Performance-99.72%35.84%35.41%21.38% Aclarion Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACONAclarion2.6905 of 5 stars$7.50-2.3%$11,758.50+156,680.0%-99.7%$4.37M$54.60K0.007News CoverageENZEnzo BiochemN/A$0.33-14.8%N/A-68.4%$17.03M$29.09M0.00520Gap DownHigh Trading VolumeBRTXBiorestorative Therapies2.7849 of 5 stars$1.67+3.5%$18.00+980.7%-15.3%$12.49M$400K-1.137MGRXMangoceuticals0.8837 of 5 stars$1.52-12.1%N/A-97.8%$7.86M$620K-0.333News CoveragePositive NewsGap DownSSYSunLink Health SystemsN/A$0.88+0.6%N/A+16.6%$6.20M$31.09M6.291,376BGLCBioNexus Gene Lab0.3642 of 5 stars$3.07+10.8%N/A+33.5%$5.53M$9.51M0.0030Gap DownVSEEVSee Health1.2541 of 5 stars$1.16+5.5%$5.00+331.0%N/A$4.18MN/A0.00N/AGap UpATIPATI Physical Therapy0.2076 of 5 stars$0.90+4.7%N/A-80.8%$3.97M$741.86M-0.055,600Upcoming EarningsGap UpDHACDigital Health AcquisitionN/A$1.10-3.5%N/A-88.6%$3.96MN/A0.002,021Gap DownOTRKOntrak2.761 of 5 stars$0.50-9.8%$45.00+8,916.2%-83.9%$2.11M$10.85M-0.03250News CoverageHigh Trading VolumeNIVFNewGenIvf GroupN/A$1.04+1.0%N/A-99.5%$543K$5.43M0.00N/APositive NewsHigh Trading Volume Related Companies and Tools Related Companies Enzo Biochem Competitors Biorestorative Therapies Competitors Mangoceuticals Competitors SunLink Health Systems Competitors BioNexus Gene Lab Competitors VSee Health Competitors ATI Physical Therapy Competitors Digital Health Acquisition Competitors Ontrak Competitors NewGenIvf Group Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ACON) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersElon’s RevengeElon Musk and President Trump's new feud is all over the news... But what no one has reported – yet – is th...Altimetry | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredGold: Now legal tender in many statesThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aclarion, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aclarion With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
